Antibodies and Vaccination (11.2): Cambridge (CIE) A Level Biology 9700 Exam Questions by Topic

Antibodies and vaccination is sub-topic 11.2 of Topic 11, Immunity, in the Cambridge International AS & A Level Biology syllabus (9700). You need to relate the molecular structure of antibodies to their functions, outline the hybridoma method for producing monoclonal antibodies and the principles of using them to diagnose and treat disease, describe the differences between active and passive immunity and between natural and artificial immunity, explain how the antigens in vaccines give long-term immunity, and explain how vaccination programmes help to control the spread of infectious diseases. This is AS content, examined on Papers 1 and 2.

The examiners' reports return to the same points. An antibody has antigen-binding sites in its variable regions; do not call them receptors or active sites. In the hybridoma method it is the antigen, not the pathogen, that is injected, and it is cells from the spleen, not antibodies, that are fused with myeloma cells. Name a type of immunity with both words, such as artificial passive. Memory cells, not antibodies, give long-term immunity, and they are formed in the primary immune response. When a question is about a vaccination programme, write about herd immunity and breaking the transmission cycle, not about the immune response.

Studying Cambridge International A level Biology and want more help? Tom teaches CIE students one-to-one online, including students in the UAE, Saudi Arabia, Hong Kong, India and Indonesia, and every lesson is recorded. You can book a one-to-one lesson or a free 15-minute discovery chat, or register your interest in a CIE group class starting in September 2027, using the links at the bottom of this page.

What you need from IGCSE

Each question on this page assumes you're secure on these ideas. If any of them feels shaky, look it up before you start.

  • Each pathogen has its own antigens, which have specific shapes, and antibodies are proteins that bind to antigens.
  • Active immunity is gained after an infection by a pathogen or by vaccination, and memory cells are produced.
  • Passive immunity is a short-term defence in which antibodies come from another individual, for example across the placenta or in breast milk.
  • A vaccine contains weakened pathogens or their antigens, which stimulate an immune response.

Key terms

These words come up in the questions and mark schemes. Examiners expect you to use them exactly.

  • Antigen-binding site: the part of an antibody, at the end of a variable region, with a shape complementary to one specific antigen.
  • Variable region: the part of each heavy and light chain whose sequence of amino acids differs between antibodies, giving each antibody its specificity.
  • Hinge region: the flexible part of an antibody that lets the variable regions move, so the antibody can bind to antigens that are different distances apart.
  • Monoclonal antibody: an antibody made by a single clone of cells, so every molecule is specific to the same antigen.
  • Hybridoma: a cell made by fusing a plasma cell (B-lymphocyte) with a myeloma cell; it secretes antibody and can divide.
  • Active immunity: immunity in which the person's own immune response produces antibodies and memory cells; it is long-lasting.
  • Passive immunity: immunity from antibodies made elsewhere; it acts immediately but is temporary, as no memory cells are produced.
  • Herd immunity: protection of people without immunity because a large proportion of the population is immune, which breaks the transmission cycle.

What these questions cover (Cambridge 9700 Topic 11: Immunity)

The questions test these learning outcomes from sub-topic 11.2 of the Cambridge International AS & A Level Biology syllabus (9700) for 2025 to 2027.

  • 11.2.1 relate the molecular structure of antibodies to their functions
  • 11.2.2 outline the hybridoma method for the production of monoclonal antibodies
  • 11.2.3 outline the principles of using monoclonal antibodies in the diagnosis of disease and in the treatment of disease
  • 11.2.4 describe the differences between active immunity and passive immunity and between natural immunity and artificial immunity
  • 11.2.5 explain that vaccines contain antigens that stimulate immune responses to provide long-term immunity
  • 11.2.6 explain how vaccination programmes can help to control the spread of infectious diseases

How to use this page

Write your answer on paper before you open the mark scheme. Allow about 1.2 minutes per mark: the 22 questions are worth 47 marks, so about 56 minutes in total. Then mark your answer strictly against the mark scheme and read the examiners' tip underneath it. If you'd rather print the questions, download the PDF pack.

Antibody structure and function (11.2.1)

Question 1

Paper 2 · May/June 2024 (21) · Q6(a)(i) · 2 marks

Explain how the structure of an antigen-binding site makes it specific to a particular antigen.

Exam question: (i) Explain how the structure of an antigen‑binding site makes it specific to a particular antigen, as shown in Fig. 6.1.
Show the mark scheme Mark scheme: any two from: 1 (antigen-binding site / variable region) has a shape that is complementary to antigen ; A tertiary / quaternary, structure 2 (antigen-binding site / variable region has) specific, sequence(s) of amino acids / primary structure(s) ; 3 idea that different amino acids have different, R-groups / side chains

Tap an image to open it full size.

From the examiners' report: Many wrote about the complementary shapes of the antigen and the antigen-binding site. The strongest answers also used protein structure: the sequence of amino acids and the folding of the variable regions. If you use the word 'epitope', it refers to the antigen, not the antibody.

Question 2

Paper 2 · May/June 2024 (21) · Q6(a)(ii) · 1 mark

State the function of the hinge region of the antibody.

Exam question: State the function of the hinge region of the antibody shown in Fig. 6.1.
Show the mark scheme Mark scheme: idea that allows flexibility for binding (to antigens) ; A at different angles for flexibility / allows variable region(s) to move

Tap an image to open it full size.

From the examiners' report: Many said that the hinge region gives flexibility but did not say why this is an advantage: the antibody can bind to antigens that are different distances apart on a pathogen. 'To hold the polypeptide chains together' did not gain credit.

Question 3

Paper 2 · February/March 2023 (22) · Q4(c) · 3 marks · Hard

Explain why different antibodies are needed to give immunity to new strains of the influenza virus.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: The influenza virus can mutate frequently to produce different strains of the virus. A new vaccine is often necessary to stimulate the production of new antibodies to these new strains. Explain why different antibodies need to be produced to give immunity to these new strains.
Show the mark scheme Mark scheme: any three from: 1 (as influenza virus mutates) antigen (proteins) altered / altered capsid proteins / AW ; 2 antibodies are specific to antigens ; 3 ref. to complementary shape (between variable regions of antibody and antigen) ; 4 ref. to variable regions / Fab, at the ends ;

Tap an image to open it full size.

From the examiners' report: A common error was to say that the viruses become resistant to the antibodies. Many answers confused antibodies with antibiotics.

The hybridoma method (11.2.2)

Question 4

Paper 2 · October/November 2025 (22) · Q2(c)(ii) · 3 marks

Name the two types of cell that fuse to form a hybridoma cell and explain why the fusion is necessary.

Exam question: The production of monoclonal antibodies for treatment involves the formation of hybridoma cells from two different cell types. Name the two types of cell that fuse to form a hybridoma cell and explain why this fusion is necessary.
Show the mark scheme Mark scheme: B-lymphocyte / plasma cell / splenocyte, and, myeloma / tumour, cell ; A B-cell for B-lymphocyte A cancer cell for myeloma cell plus two from: (B-lymphocyte) synthesises (specific / desired) / AW, antibody ; I has the antibody (B-lymphocyte) cannot survive (for long) / dies, in culture ; (myeloma cell) can divide / can

Tap an image to open it full size.

Question 5

Paper 2 · February/March 2024 (22) · Q6(d) · 3 marks

Outline how anti-CCR5 monoclonal antibodies can be made using the hybridoma method.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: The use of monoclonal antibodies against the CCR5 coreceptor protein (anti-CCR5) has been shown to be effective in the treatment of HIV infection. Outline how anti-CCR5 monoclonal antibodies can be synthesised in the laboratory using the hybridoma method.
Show the mark scheme Mark scheme: any three from: 1 (named) small mammal, injected / AW, with CCR5 ; A antigen 2 immune response occurs (over several weeks) ; A immune response described 3 plasma cells / B-lymphocytes / B-cells / splenocytes, extracted from spleen ; 4 plasma cells / B-lymphocytes / B-cells, fused with, myeloma / tumour / cancer / AW, c

Tap an image to open it full size.

Question 6

Paper 2 · October/November 2018 (22) · Q4(c)(i) · 1 mark

State what is injected into the mouse in step 1 of the flow chart.

Exam question: State what is being injected into the mouse in step 1.
Show the mark scheme Mark scheme: (HIV) antigen / p24 ; A capsid protein / capsomere(s) / protein coat R HIV

Tap an image to open it full size.

From the examiners' report: Most who lost the mark said that the virus itself, HIV-1, was injected. An antigen alone, here the viral protein p24, can stimulate an immune response in the mouse. Human blood and antibodies to HIV-1 were also wrong.

Question 7

Paper 2 · October/November 2018 (22) · Q4(c)(ii) · 1 mark

Explain why several weeks, not several days, separate step 1 and step 2.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Explain why several weeks, rather than several days, separates step 1 and step 2.
Show the mark scheme Mark scheme: (time needed) so, immune response / clonal expansion / production of B-lymphocytes / production of plasma cells, can occur ; A B-cells / splenocytes R plasma cells need to multiply I ref. to antibody production

Tap an image to open it full size.

From the examiners' report: Use the term immune response. The time is not for the mouse to make the antibody: step 2 removes cells from the spleen. Memory cells were not relevant.

Question 8

Paper 2 · October/November 2018 (22) · Q4(c)(iii) · 1 mark

State one feature of the myeloma cells that is essential for the process.

Exam question: State one feature of the myeloma mouse cells, used in step 3, that is essential for this production process.
Show the mark scheme Mark scheme: any one from immortal / long-lived ; able to replicate / capable of cell division ; uncontrolled cell division, can grow / survive, in cell culture ; cannot grow on, HAT / hypoxanthine-aminopterin-thymidine / step 4, (culture) medium ; A do not have gene coding for ability to grow on HAT

Tap an image to open it full size.

From the examiners' report: Most correct answers were about the ability of myeloma cells to divide; that they are long-lived was the next most common. Myeloma cells do not produce large quantities of antibody.

Question 9

Paper 2 · October/November 2018 (22) · Q4(c)(iv) · 1 mark

Name the fused cells formed in step 4.

Exam question: Name the fused cells formed in step 4.
Show the mark scheme Mark scheme: hybridoma ;

Tap an image to open it full size.

From the examiners' report: Most knew that these are hybridoma cells. Plasma cells, B-lymphocytes and 'hybrid cells' were the usual wrong answers.

Question 10

Paper 2 · October/November 2018 (22) · Q4(c)(v) · 1 mark

Suggest why the cells are screened in step 6.

Exam question: Suggest why step 6 is necessary.
Show the mark scheme Mark scheme: any one from (check cells for) production / AW, (by hybridoma cells) of, anti-HIVp24 antibody / antibody against p24 ; A the antibody / monoclonal antibody A check cells, contain / have / AW, desired antibody / AW idea that only want cells that produce desired antibody / do not want cells that produce different antibod

Tap an image to open it full size.

From the examiners' report: Not all hybridoma cells secrete the antibody specific for p24, so the ones that make the desired antibody have to be found and only these cultured. Step 6 is not for harvesting the antibody, and repeating the wording of step 6 gained nothing.

Monoclonal antibodies in diagnosis (11.2.1 and 11.2.3)

Question 11

Paper 2 · May/June 2022 (22) · Q2(b)(i) · 2 marks

Explain how the structure of the monoclonal antibodies in the dipstick makes them specific.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Explain how the structure of the monoclonal antibodies in the dipstick allows them to be specific in their action.
Show the mark scheme Mark scheme: allow antibody or mAb or Mab for monoclonal antibody I ref. to receptor I active site I combines / bonds any two from: specific / different, (Vibrio / pathogen) antigen-binding sites / binding sites for antigen ; R if antibody described as enzyme A (each) mAb binds to a, specific / particular, (Vibrio / pathogen) antig

Tap an image to open it full size.

From the examiners' report: Give the structural detail: antigen-binding sites, variable regions and a shape complementary to the antigen. The hinge region and constant regions were not relevant. 'Receptor' and 'active site' are the wrong terms for an antibody.

Question 12

Paper 2 · May/June 2022 (22) · Q2(b)(ii) · 3 marks · Easy

State and explain what the dipstick results show for person A and person B.

Exam question: Fig. 2.2 shows the results for samples taken from two different people, A and B, who are suspected of having cholera. 4 4 3 3 2 2 1 1 person A person B Fig. 2.2 With reference to Fig. 2.2, state and explain the conclusions that can be drawn from the results of the RDT dipsticks f
Show the mark scheme Mark scheme: allow antibody or mAb or Mab for monoclonal antibody any three from: 1 person A, has cholera O1 / is infected with V. cholerae O1 and person B, does not have cholera ; A ref. to person A testing positive for cholera O1 and person B testing negative to cholera 2 tests are, valid / working, because, controls / bands 4, s

Tap an image to open it full size.

From the examiners' report: Most made the correct diagnoses and explained that the band in control area 4 shows the results are valid. Be precise: say that antigen-antibody complex O1 has formed for person A. The complexes form on the dipstick, not inside the body.

Question 13

Paper 2 · May/June 2025 (22) · Q6(c)(i) · 1 mark

Complete the diagram to show the test well after step 5 of the sandwich ELISA.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Complete Fig. 6.4 to show the situation in the test well after step 5. Fig. 6.4
Show the mark scheme Mark scheme: (each) detection antibody attached to a (different) toxin ; allow one antibody attached to two toxins (astride) A at least one detection antibody attached R if one detection antibody attached directly to immobilised antibody R if unattached detection antibody shown

Tap an image to open it full size.

Question 14

Paper 2 · May/June 2025 (22) · Q6(c)(ii) · 1 mark

Describe one difference between the capture antibody and the detection antibody.

Exam question: With reference to Fig. 6.3, describe one difference between the capture antibody and the detection antibody.
Show the mark scheme Mark scheme: any one from: bind, to different, locations / sites / AW, on toxin ; AW A bind different, epitopes / antigenic determinants detection antibody has, HRP / enzyme (attached) ; ora ignore similarity of both bind toxin to award if stated detection antibody has enzyme capture antibody is immobilised ; ora

Tap an image to open it full size.

Monoclonal antibodies in treatment (11.2.3)

Question 15

Paper 2 · May/June 2018 (22) · Q6(b) · 2 marks

Outline the use of monoclonal antibodies in the treatment of disease.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Outline the use of monoclonal antibodies in the treatment of disease.
Show the mark scheme Mark scheme: two from: treatment of disease I statements about locating or diagnosis of disease specific / targeted, therapy / treatment ; A specific to diseased, cells / tissue A examples bind to / recognition of, receptors / antigens, on cell surface (of diseased cells) ; kill the cell by stimulating the immune system / AW ; A co

Tap an image to open it full size.

From the examiners' report: Vague answers said that monoclonal antibodies are put into the body of a person with a disease but gave little detail of how they act. Writing about detecting or diagnosing disease, or about how monoclonal antibodies are produced, did not answer the question.

Active, passive, natural and artificial immunity (11.2.4)

Question 16

Paper 2 · October/November 2025 (22) · Q2(c)(i) · 4 marks

Complete the table to compare an oral cholera vaccine with passive immunisation for cholera.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Complete Table 2.1 to compare an OCV and passive immunisation for cholera: • fill in the empty box in row 1 • circle the correct answers from the choices given in rows 3, 4 and 5. Table 2.1 passive immunisation row feature oral cholera vaccine for cholera component causing the 1
Show the mark scheme Mark scheme: antigen is a standalone mark then move to rows 3,4,5 if no marks gained from rows 3,4,5, check for correct answers in these rows going down the column to award 1 mark row feature oral cholera vaccine passive immunisation for cholera 1 component causing the antigen(s) ; I weak / weakened / toxin antibody desired respons

Tap an image to open it full size.

Question 17

Paper 2 · February/March 2025 (22) · Q4(b)(i) · 1 mark

Use the graph of antibody concentration to state the type of immunity that results from the injection.

Exam question: State the type of immunity that results from the injection given as protection against disease F.
Show the mark scheme Mark scheme: passive and artificial ;

Tap an image to open it full size.

From the examiners' report: Not everyone gave both words. The answer needed passive and artificial.

Question 18

Paper 2 · February/March 2025 (22) · Q4(b)(ii) · 2 marks

Describe features of the type of immunity that results from the injection.

Exam question: Describe features of the type of immunity resulting from the injection given as protection against disease F.
Show the mark scheme Mark scheme: any two from: temporary / short term ; immediate effect ; involves injection of, antibodies immunoglobulin ; does not, stimulate the immune system / initiate a primary immune response ; AVP ; e.g. no memory cells produced no new antibodies made

Tap an image to open it full size.

From the examiners' report: Many said that an injection of antibodies gives immediate immunity, and some added that it is only short term. Some included the idea that there is no immune response, so no memory cells are produced.

Vaccines and long-term immunity (11.2.5)

Question 19

Paper 2 · May/June 2024 (22) · Q2(c) · 4 marks

Suggest and explain the advantages of using the BCG vaccine to prevent and control TB.

Exam question: Research has shown that vaccination programmes are cost effective and are very helpful in the prevention and control of TB. The programmes may be aimed at particular groups of people that are at a high risk of getting the disease, or they may be aimed at an entire population beca
Show the mark scheme Mark scheme: any four from: 1 cells are replicating / AW (because live vaccine) ; 2 high / increased / AW, levels of (non-self / foreign) antigen (because live vaccine) ; 3 (so) strong / effective / good / AW, (primary) immune response ; A described e.g. (T-/B-) memory cells are formed idea that memory cells present when Mycobacter

Tap an image to open it full size.

From the examiners' report: Freeze-dried does not mean that the vaccine has to be kept frozen or cold. Say that memory cells form as a result of the primary immune response; antibodies are not memory cells and do not stay in the blood ready for a secondary response. Very few saw that a live vaccine means more antigen and so a stronger immune response.

Question 20

Paper 2 · October/November 2016 (22) · Q5(c) · 3 marks · Hard

Explain how vaccination can control infectious diseases.

Exam question: Explain how vaccination can control infectious diseases.
Show the mark scheme Mark scheme: (c) three from 1 vaccination, gives (active) immunity / stimulates an immune response ; must be in context of active artificial immunity 2 detail ; e.g. primary immune response clonal, selection / expansion (specific, B / T, lymphocytes) formation of antibodies formation of memory cells artificial active (immunity) 3 s

Tap an image to open it full size.

From the examiners' report: The best answers covered herd immunity and breaking the transmission cycle as well as immunity in the individual. Memory cells, not antibodies, remain after a primary response. A secondary immune response is a response to the pathogen and its antigens, not to 'disease' or 'infection'.

Vaccination programmes (11.2.6)

Question 21

Paper 2 · February/March 2023 (22) · Q4(d)(i) · 3 marks

Explain how vaccination programmes can help to control the spread of infectious diseases such as polio.

Information from earlier in this question:

Earlier part of the same exam question, giving the information this part uses. Exam question: Explain how vaccination programmes can help to control the spread of infectious diseases, such as polio.
Show the mark scheme Mark scheme: for children, allow people for polio allow disease any three from: 1 ref. to vaccination programme aims to vaccinate, whole populations / large numbers ; 2 vaccine allows (most), children / people, to have an immune response (against antigens of the disease organism) ; 3 develop, long-term immunity / artificial active

Tap an image to open it full size.

From the examiners' report: Strong answers referred to herd immunity, and the more detailed ones to breaking the transmission cycle. Some wrote about how a vaccination works and not about vaccination programmes.

Question 22

Paper 2 · October/November 2019 (22) · Q5(e) · 4 marks · Hard

Explain the difficulties faced by researchers in developing a malaria vaccine.

Exam question: After many years of intense research and development, WHO reported in 2016 that a pilot vaccination programme would be trialled between 2017 and 2020. The programme uses a vaccine acting against the most widespread species of Plasmodium. Explain the difficulties faced by research
Show the mark scheme Mark scheme: any four from: 1 (Plasmodium) is a, eukaryote / protoctist, so has many antigens ; R bacterium / virus, is a eukaryote or (Plasmodium) has many genes coding for (different) antigens ; I antigenic variation 2 idea that different Plasmodium species have different antigens ; I antigenic variation I strains for species 3 (

Tap an image to open it full size.

From the examiners' report: Write about developing a vaccine, not the general problems of vaccines already in use. Different species of Plasmodium have different antigens: 'strains' is the wrong word. As a eukaryote, each species has many antigens, not one.

Where students lose marks (from Cambridge examiners' reports and mark schemes)

Each point below comes from the examiners' reports and mark schemes, and is followed by wording that gained marks.

  • Antibodies don't have active sites. Students used 'receptor' or 'active site' for the part of the antibody that binds the antigen, or wrote about the hinge and constant regions.

    ✔ Gains credit: 'specific antigen-binding sites', a 'specific variable region', and 'binding site and antigen have complementary shapes'.

  • Say why the hinge matters. Students wrote 'flexibility' with no reason, or 'to hold the polypeptide chains together'.

    ✔ Gains credit: the hinge region 'allows flexibility for binding to antigens', or 'allows variable regions to move'.

  • Inject the antigen, not the pathogen. Students said that the virus, HIV-1, was injected into the mouse.

    ✔ Gains credit: 'HIV antigen' or 'p24'; the mark scheme rejects 'HIV'.

  • Myeloma cells divide; they don't make antibody. Students suggested that myeloma cells produce large quantities of antibody.

    ✔ Gains credit: myeloma cells are 'immortal' or 'long-lived', 'capable of cell division' and 'can survive in cell culture'.

  • Screening finds the right hybridomas. Students thought step 6 was for harvesting the antibody, or for checking that the cells were safe to give to people.

    ✔ Gains credit: the cells are checked for 'production of anti-HIVp24 antibody' because you 'only want cells that produce desired antibody'.

  • Name both parts of the immunity. Students gave only 'passive' or only 'artificial' for immunity from an injection of antibodies.

    ✔ Gains credit: 'passive and artificial'; it is 'temporary', has an 'immediate effect' and there are 'no memory cells produced'.

  • Memory cells, not antibodies, last. Students suggested that antibodies act as memory cells or stay in the blood for a secondary response, or wrote about memory cells 'remembering' the infection.

    ✔ Gains credit: 'memory cells are formed' in a 'strong primary immune response', which 'provides artificial active immunity', so a 'secondary response occurs when Mycobacterium infects'.

  • Programmes protect the population. Students explained how a vaccination works and did not write about vaccination programmes.

    ✔ Gains credit: a programme 'aims to vaccinate whole populations', giving 'herd immunity'; 'vaccinated individuals cannot transmit virus', which helps to 'break the transmission cycle'.

Download the questions

Download the PDF pack (22 questions, mark schemes at the end)

Keep practising

Questions, mark schemes and examiners' report extracts © Cambridge University Press & Assessment.